Hologram Sciences, Royal DSM’s consumer brand for personalized nutrition, adds at-home diagnostics and monitoring features for women’s health and fertility

Hologram Sciences announced a new consumer brand called Phenology, rolling out first in North America, that will offer at-home diagnostics for women before, during, and after menopause.

Hologram Sciences (New York City), the consumer-facing personalized nutrition brand introduced by Royal DSM (Boston, MA) last year, is adding diagnostics and monitoring tools to its offerings aimed at providing women with insights related to their menopause and fertility health. “The company is building its product offering around an innovative portfolio of nutritional supplements and wellness products, symptom tracking, and advice delivered through a digital platform,” it said in a press release.

Hologram Sciences announced a new consumer brand called Phenology, rolling out first in North America, that will offer at-home diagnostics for women before, during, and after menopause. Overseen by a team of female scientists and advisors, the program will include at-home diagnostic tools for hormone tracking, plus custom insights, advice, and one-on-one coaching personalized to each customer’s needs. Users can then follow a wellness program that includes dietary supplements and other wellness products.

The Phenology website states, “Your unique experience of menopause, influenced by genetics, lifestyle, and environment, will manifest in ways unique to you. That’s why only a personalized approach with tailored remedies will do. By paying careful attention to the right signs and signals, Phenology prepares you for what comes next so you can embrace this new season and emerge your best self.”

Hologram Sciences also announced an exclusive new partnership with Germany-based tech startup Inne, which has created what the companies say is “the world’s first at-home non-invasive fertility monitoring system.” The diagnostic and tracking platform measures hormone levels using saliva. DSM’s investment firm, DSM Venturing, is one of the investors in Inne. Inne and Hologram Sciences will focus on developments around new analytes and commercializing the technology.

In a press release, CEO of Hologram Sciences, Ian Brady, said, “The importance of usable, convenient, and non-invasive testing devices cannot be underestimated. Until recently, many diagnostics could only be reliably performed on blood, and we are thrilled to be announcing our partnership with Inne as they offer a genuine alternative for a range of biomarkers. Going forward, this will be key to the easy adoption of personalized nutrition solutions by consumers and we will be working tightly with Inne on integrating their platform as a crucial component in our concepts as we build a future of better personalized health.”